Clinical trials: Glucocorticoids
Respiration Disorders, Body Composition, Beneficial
The Austrian LEAD (Lung hEart sociAl boDy) Study
The LEAD study is the first longitudinal cohort investigating respiratory, cardiac, and metabolic health in a reference population of Austria.
- Conditions
- Respiration Disorders, Body Composition, Beneficial, Metabolic Health
- Trial name
- LEAD (NCT01727518)
- Testing
- As the LEAD study is an observational cohort study, there is no intervention to report.
- Where
- Austria
- Volunteers
- 14,966 people, healthy volunteers welcome
- Sponsor
- Ludwig Boltzmann Institute for Lung Health
Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 year of age with Glucocorticoid (GC)-induced…
- Trial name
- NCT03164928
- Testing
- Denosumab
- Where
- 38 sites in United States, Australia and 11 more
- Volunteers
- 24 people
- Sponsor
- Amgen